XOMA Royalty (XOMAP) Stock Analysis

What XOMA Royalty does

XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Key metrics

ETFs linked to XOMAP

Broad-market and Healthcare sector ETFs an investor holding XOMA Royalty is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how XOMAP fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for XOMA Royalty?

XOMA Royalty trades under the ticker XOMAP on NASDAQ.

Which exchange is XOMAP listed on?

XOMAP is listed on NASDAQ.

What sector does XOMA Royalty operate in?

XOMA Royalty is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze XOMAP in a portfolio?

PortView shows XOMAP's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.